PHAR earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 65.66. Updated 2026-07-23.
Pharming Group (PHAR) Research Hub
Pharming Group (PHAR) trades on NASDAQ, NL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.21 USD (+2.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 65.66, market cap 0.94B. This hub links to the full technical, earnings and options research available for PHAR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, NL |
| Last close | 11.21 USD (+2.19%) |
| 52-week range | 9.62 USD – 14.5 USD |
| Trend regime | Range |
| 14-day RSI | 52.7 (Neutral) |
| Trailing P/E | 65.66 |
| Market cap | 0.94B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for PHAR
Covered Call on PHAR: how it works, illustrative setup around the real 11.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PHAR: how it works, illustrative setup around the real 11.21 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PHAR: how it works, illustrative setup around the real 11.21 USD price, max profit/loss, breakeven and when to use it. Educational.
PHAR technical analysis: range, last 11.21 USD, RSI 52.7, 52w range 9.62 USD–14.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PHAR in?
Pharming Group (PHAR) is classified under Healthcare (Biotechnology), listed on NASDAQ, NL.
Is PHAR in an uptrend or downtrend?
As of 2026-09-11, PHAR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PHAR's trailing P/E ratio?
PHAR's trailing P/E is 65.66, with a market cap of 0.94B. See the earnings research page for full valuation detail.
When does PHAR next report earnings?
PHAR is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 0.063 USD.